Featured Research

from universities, journals, and other organizations

Pandemic 2009 H1N1 vaccination produces antibodies against multiple flu strains

Date:
May 21, 2012
Source:
Emory University
Summary:
The pandemic 2009 H1N1 vaccine can generate antibodies in vaccinated individuals not only against the H1N1 virus, but also against other influenza virus strains including H5N1 and H3N2. This discovery adds an important new dimension to the finding last year that people infected with pandemic 2009 H1N1 virus produced high levels of antibodies that were broadly cross-reactive against a variety of flu strains.

The pandemic 2009 H1N1 vaccine can generate antibodies in vaccinated individuals not only against the H1N1 virus, but also against other influenza virus strains including H5N1 and H3N2. This discovery adds an important new dimension to the finding last year that people infected with pandemic 2009 H1N1 virus produced high levels of antibodies that were broadly cross-reactive against a variety of flu strains.

Development of a "universal" influenza vaccine that protects against multiple viral subtypes has long been the goal of immunologists working to overcome the requirement for a new vaccine during each flu season and the need for a rapid response to potentially dangerous mutations.

The new discovery brings the researchers closer to being able to design a pan-influenza vaccine that reliably induces broadly cross-reactive antibodies at sufficiently high levels to protect against different influenza subtypes.

The findings are published this week in the Proceedings of the National Academy of Sciences (PNAS). The researchers are from Emory University, the University of Chicago, and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

The researchers analyzed B cell (antibody) responses in 24 healthy adults immunized with the inactivated pandemic 2009 H1N1 vaccine. Vaccination caused a rapid increase in production of monoclonal antibodies that were capable of neutralizing multiple flu strains. Three of the antibody types also were able to stick to the "stalk" region of the virus that does not change as much as other regions and thus could provide a basis for a vaccine with broader and more reliable protection.

Antibodies that are broadly reactive against multiple influenza strains are rarely seen in people after infection or vaccination with seasonal flu, the authors note. In the 24 vaccinated individuals in the current study, the majority of flu antibodies neutralized more than one influenza strain and also seemed to be the result of B-cell memory resulting from previous exposure to other flu strains.

"Since discovering last year that people infected with the H1N1 2009 virus produced antibodies against multiple flu strains, our goal has been to test this ability in vaccinated individuals," says senior author Rafi Ahmed, PhD, director of the Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar.

"Our new finding is a key step in the development of a vaccine that can produce high levels of antibodies that protect against multiple flu strains, including challenging mutations that have the potential for widespread illness and death."

The next step for the research team will be to improve on their results and develop a vaccine that produces high levels of antibodies and can reliably protect against multiple flu subtypes.

First authors of the paper are Gui-Mei Li, PhD, and Christopher Chiu, PhD, postdocs at the Emory Vaccine Center and Emory University School of Medicine. Senior authors are Ahmed and Patrick C. Wilson, PhD, from The Knapp Center for Lupus and Immunology Research at the University of Chicago.

Other authors include Jens Wrammert, Megan McCausland, Srilatha Edupuganti, Mark Mulligan, and Aneesh K. Mehta from Emory; Sarah F. Andrews, Nai-Ying Zheng, Jane Hwei-Lee, Min Huang, Xinyan Qu from the University of Chicago; and Duman R. Das and Jonathan W. Yewdell from the NIAID.

The research was funded in part by NIH/NIAID grant U19-A1057266 with American Recovery and Reinvestment Act Supplement U19-A1057266-06S2; NIH/NIAID awards HHSN266200700006C Center of Excellence for Influenza Research and Surveillance; HHSN2662005000026C; and 5U19A1062629-05; and the Intramural Research Program of the NIAID.


Story Source:

The above story is based on materials provided by Emory University. The original article was written by Holly Korschun. Note: Materials may be edited for content and length.


Journal Reference:

  1. G.-M. Li, C. Chiu, J. Wrammert, M. McCausland, S. F. Andrews, N.-Y. Zheng, J.-H. Lee, M. Huang, X. Qu, S. Edupuganti, M. Mulligan, S. R. Das, J. W. Yewdell, A. K. Mehta, P. C. Wilson, R. Ahmed. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proceedings of the National Academy of Sciences, 2012; DOI: 10.1073/pnas.1118979109

Cite This Page:

Emory University. "Pandemic 2009 H1N1 vaccination produces antibodies against multiple flu strains." ScienceDaily. ScienceDaily, 21 May 2012. <www.sciencedaily.com/releases/2012/05/120521163745.htm>.
Emory University. (2012, May 21). Pandemic 2009 H1N1 vaccination produces antibodies against multiple flu strains. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/05/120521163745.htm
Emory University. "Pandemic 2009 H1N1 vaccination produces antibodies against multiple flu strains." ScienceDaily. www.sciencedaily.com/releases/2012/05/120521163745.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins